By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


APEIRON Biologics AG 

Campus-Vienna-Biocenter 5

Vienna    1030  Austria
Phone: 43-1-865-65-77 Fax: 43-1-865-65-77-800




Company News
Marketing Approval For Children’s Cancer Immunotherapy In The EU: Outstanding Success For Privately Financed Austrian Biotech Company APEIRON 5/12/2017 11:32:34 AM
EUSA Pharma And APEIRON Receive Positive CHMP Opinion For Dinutuximab Beta For The Treatment Of High-Risk Neuroblastoma In Europe 3/27/2017 7:04:19 AM
APEIRON And Columbia University Have Entered Into An Exclusive License Agreement That Expands Apeiron's Immune Checkpoint Blockade IP Portfolio 2/16/2016 9:38:22 AM
APEIRON Biologics AG Collaborates With Idis Ltd to Initiate Managed Access Program 9/25/2013 8:29:53 AM
Rentschler Biotechnologie GmbH & Co. Produces APEIRON Biologics AG's Monoclonal Antibody APN311 for Late Stage Clinical Development and Market 8/1/2013 8:10:42 AM
APEIRON Biologics AG Release: Success in Avoiding Radiation Skin Damage for Breast Cancer Patients 3/5/2013 11:33:56 AM
APEIRON Biologics AG Closes Regional License Agreement for Antibody-Based Immunotherapy 1/18/2013 9:31:54 AM
APEIRON Biologics AG Establishes Biotech-Spinoff Attoquant Diagnostics 12/4/2012 11:55:18 AM
APEIRON Biologics AG Initiates Clinical Study to Investigate Prevention of Radiation-Induced Skin Damage in Breast Cancer Patients 2/27/2012 12:10:39 PM
APEIRON Biologics AG Release: Start of Phase IIa Study in Acute Lung Injury Patients Marks Development Milestone 12/19/2011 10:46:41 AM